BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16528526)

  • 1. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
    Umeda M; Okuda S; Izumi H; Nagase D; Fujimoto Y; Sugasawa Y; Arai C; Natori K; Katoh M; Kuraishi Y
    Ann Hematol; 2006 Jul; 85(7):469-73. PubMed ID: 16528526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
    Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
    Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
    Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma.
    Kim JE; Yoo C; Lee DH; Kim SW; Lee JS; Suh C
    Ann Hematol; 2010 Apr; 89(4):391-7. PubMed ID: 19844712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
    Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
    Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of telomerase activity in multiple myeloma.
    Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
    Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
    Pasqualetti P; Colantonio D; Casale R; Lorenzetti G; Natali G
    Recenti Prog Med; 1989 Oct; 80(10):543-6. PubMed ID: 2602637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.
    Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E
    Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
    Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
    Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
    Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
    Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
    Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
    Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors in multiple myeloma].
    Pick AI; Tamir R; Vana D; Duczyminer-Kahana M; Weiss H; Lurie H; Dawidowich J; Meyerson E; Gelernter I
    Harefuah; 1990 Apr; 118(8):437-42. PubMed ID: 2358224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.